

Claims 1-87 (Canceled).

88. (Currently Amended) A method of determining the presence or absence of dysplastic or neoplastic cells in a test sample containing cells from an individual, wherein the test sample comprises a specimen selected from the group consisting of sputum, bronchio-alveolar lavage specimens, urine, breast duct fluid, brushings from the alimentary tract, and cervical, fecal or urine cytology smears, the method comprising:

contacting the test sample with an antibody or antibody fragment directed against Minichromosome Maintenance protein 2 (MCM2 protein); and

determining amount and/or pattern of binding of said antibody or antibody fragment to said test sample;

whereby an increase in said amount and/or a difference in said pattern if detected for the test sample compared with normal is indicative of presence of dysplastic or neoplastic cells in said test sample.

89. (Previously Added) A method according to claim 88 wherein binding of said antibody or antibody fragment to MCM2 protein in the test sample is indicative of the presence of dysplastic or neoplastic cells in said test sample.

90. (Previously Added) A method according to claim 88 wherein a difference in pattern of binding of said antibody or antibody fragment to said test sample compared

with normal is indicative of the presence of dysplastic or neoplastic cells in said test sample.

Claims 91-100 (Canceled).

101. (Previously Added) A method according to claim 88 wherein the sample is provided from fluid taken from the individual.

102. (Previously Added) A method according to claim 101 wherein a sample of cells is provided from said fluid.

Claim 103. (Canceled).

104. (Previously Added) A method according to claim 101 wherein the fluid is urine.

105. (Previously Added) A method according to claim 88 wherein a population of individuals is screened.

Claim 106. (Canceled).

107. (Currently Amended) A method according to claim ~~106~~ 88 wherein the sample is a cervical smear.

108. (Previously Added) A method according to claim 107 wherein binding of said antibody or antibody fragment to MCM2 protein in the cervical smear is indicative of the presence of dysplastic or neoplastic cells in said cervical smear.

109. (Currently Amended) A method according to claim ~~106~~ 107 wherein a population of individuals is screened.

110. (new) A method according to claim 101 wherein a population of individuals is screened.

111. (new) A method according to claim 104 wherein a population of individuals is screened.

---